logo
Share SHARE
FONT-SIZE Plus   Neg

Jury Rules In Favor Of Smith & Nephew In Hologic Litigation - Quick Facts

Hologic Inc. (HOLX) announced that the jury returned a verdict in favour of Smith & Nephew (SNN, SN.L) in the patent infringement suit between the companies.

On June 9, 2010 and November 22, 2011, S&N filed suit in the United States District Court for the District of Massachusetts alleging infringement of U.S. Patents 7,226,459 and 8,061,359 by the use and sale of the MyoSure Tissue Removal Device. The two patent suits were consolidated into a single action culminating in a jury trial which commenced on August 20, 2012. On September 4, 2012, the jury in the trial returned a verdict in S&N's favor.

As a part of this verdict, the jury awarded S&N the sum of $4 million as damages for lost profits. Hologic, in connection with the acquisition of Interlace Medical, Inc. , the developer of the MyoSure product, is indemnified up to a previously defined dollar amount by the former Interlace Medical shareholders for potential associated liabilities.

"We are disappointed in and strongly disagree with the verdict in this case," said Mark Casey, Hologic's Senior Vice President, Chief Administrative Officer and General Counsel.

"This is but the first step in a multi-phase process and there remain several issues to be decided by the Court which could impact the applicability of this verdict. We intend to continue to market and sell the MyoSure product and, if necessary, will pursue the appellate process to ensure the right of women to have access to this best-in-class treatment for the removal of uterine fibroids," said Mark Casey.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Verizon Communications Inc. (VZ) reported Thursday flat profit in the third-quarter 2017, but quarterly total consolidated operating revenues increased 2.5 percent from the prior year. The adjusted earnings per share met analysts' expectations. The company reaffirmed outlook for its fiscal year 2017. But it now expects capital spending for 2017 to be at the lower end of the prior range. Swiss nutrition, health and wellness giant Nestle SA reported a slight decline in reported sales for the nine-month period, reflecting divestments and negative currency impact. Organic sales growth was 2.6 percent, supported by improved real internal growth or RIG of 1.8 percent and pricing of 0.8 percent. The company now projects trading operating profit margin to decrease by 40-60 basis points.. While Democrats have largely been critical of the Republican tax reform plan, President Donald Trump has claimed the proposal has some bipartisan support. Trump suggested to reporters ahead of a meeting with members of the Senate Finance Committee on Wednesday that "people on both sides" support the tax reform plan.
comments powered by Disqus
Follow RTT